MeiraGTx Holdings (Nasdaq:MGTX) - Aandelenkoers, Nieuws & Analyse

MGTX Overzicht aandelen

MeiraGTx Holdings plc, een klinisch gentherapiebedrijf dat zich richt op de ontwikkeling van behandelingen voor patiënten met ernstige ziekten.

Over het bedrijf

MGTX fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 7.79% per jaar groeien

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar verwaterd

MeiraGTx Holdings plc Concurrenten

REGENXBIO

NasdaqGS:RGNX

US$434.4m

iTeos Therapeutics

NasdaqGM:ITOS

US$321.8m

C4 Therapeutics

NasdaqGS:CCCC

US$396.0m

Alector

NasdaqGS:ALEC

US$488.6m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor MeiraGTx Holdings
Historische aandelenkoersen
Huidige aandelenkoers	US$5.96
52 Week Hoogtepunt	US$7.60
52 Week Laag	US$3.85
Bèta	1.29
11 maand verandering	43.61%
3 maanden verandering	34.23%
1 Jaar Verandering	16.86%
33 jaar verandering	-70.83%
5 jaar verandering	-61.40%
Verandering sinds IPO	-60.27%

Recent nieuws en updates

MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings

Oct 15

Recent updates

MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings

Oct 15

MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts

Jul 15

MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are Reducing Their Forecasts For This Year

Mar 16

MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are More Bearish Than They Used To Be

Nov 16

MeiraGTx GAAP EPS of -$0.76, revenue of $10.76M

Aug 11

MeiraGTx inks $100M debt agreement backed by manufacturing facilities

Aug 03

MeiraGTx Holdings (NASDAQ:MGTX) Is In A Good Position To Deliver On Growth Plans

Apr 29

Analysts' Revenue Estimates For MeiraGTx Holdings plc (NASDAQ:MGTX) Are Surging Higher

Mar 15

MeiraGTx: Perceptive's Large Stake Makes It Interesting

Jan 19

MeiraGTx Holdings (NASDAQ:MGTX) Is In A Good Position To Deliver On Growth Plans

Dec 28

Rendement voor aandeelhouders

	MGTX	US Biotechs	US Markt
7D	1.4%	-1.4%	-1.9%
1Y	16.9%	20.2%	30.4%

Rendement versus industrie: MGTX presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 20.2 % opleverde.

Rendement versus markt: MGTX presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.4 % opleverde.

Prijsvolatiliteit

Is MGTX's price volatile compared to industry and market?
MGTX volatility
MGTX Average Weekly Movement	9.2%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: MGTX heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van MGTX is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2015	387	Alexandria Forbes	meiragtx.com

MeiraGTx Holdings plc is een klinisch gentherapiebedrijf dat zich richt op de ontwikkeling van behandelingen voor patiënten met ernstige ziekten. Het bedrijf ontwikkelt verschillende therapieën voor oogziekten, waaronder erfelijke netvliesaandoeningen en grote degeneratieve oogziekten, neurodegeneratieve ziekten en xerostomie. De programma's in klinische ontwikkeling omvatten Fase I/II klinische fase programma's in achromatopsie, X-gebonden retinitis pigmentosa, en RPE65-deficiëntie; Fase I klinische studies voor stralingsgeïnduceerde xerostomie; en Parkinson programma dat een Fase II studie heeft voltooid.

MeiraGTx Holdings plc Samenvatting

Hoe verhouden de winst en inkomsten van MeiraGTx Holdings zich tot de beurswaarde?
MGTX fundamentele statistieken
Marktkapitalisatie	US$449.69m
Inkomsten(TTM)	-US$93.14m
Inkomsten(TTM)	US$8.12m

56.8x

P/S-verhouding

-5.0x

Koers/Winstverhouding

Is MGTX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
MGTX resultatenrekening (TTM)
Inkomsten	US$8.12m
Kosten van inkomsten	US$0
Brutowinst	US$8.12m
Overige uitgaven	US$101.27m
Inkomsten	-US$93.14m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.20
Brutomarge	100.00%
Nettowinstmarge	-1,146.81%
Schuld/Eigen Vermogen Verhouding	90.8%

Hoe presteerde MGTX op de lange termijn?

Bekijk historische prestaties en vergelijking

MGTX Overzicht aandelen

Beloningen

Risicoanalyse

MeiraGTx Holdings plc Concurrenten

NasdaqGS:RGNX

US$434.4m

NasdaqGM:ITOS

US$321.8m

NasdaqGS:CCCC

US$396.0m

NasdaqGS:ALEC

US$488.6m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

MeiraGTx Holdings plc Announces Positive Data from Randomized, Sham-Controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease

MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings

Consensus revenue estimates fall by 35%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

MeiraGTx Holdings plc has completed a Follow-on Equity Offering in the amount of $50 million.

Price target increased by 40% to US$21.20

Recent updates

MeiraGTx Holdings plc Announces Positive Data from Randomized, Sham-Controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease

MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings

Consensus revenue estimates fall by 35%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

MeiraGTx Holdings plc has completed a Follow-on Equity Offering in the amount of $50 million.

Price target increased by 40% to US$21.20

Price target decreased by 19% to US$17.50

MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts

MeiraGTx Holdings (NASDAQ:MGTX) Has Debt But No Earnings; Should You Worry?

Consensus revenue estimates decrease by 11%, EPS upgraded

First quarter 2024 earnings released: US$0.32 loss per share (vs US$0.62 loss in 1Q 2023)

MeiraGTx Holdings plc, Annual General Meeting, Jun 06, 2024

MeiraGTx Holdings plc Appoints Dr. Debra Yu to Serve on Each of the Compensation Committee and Science and Technology Committee of the Board

Price target decreased by 10.0% to US$21.60

New major risk - Financial position

MeiraGTx: Bota-Vec Program Advancing With Milestones Being Met

CEO, President & Director exercised options and sold US$101k worth of stock

CEO, President & Director exercised options and sold US$587k worth of stock

Forecast to breakeven in 2025

MeiraGTx Holdings plc has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

MeiraGTx Holdings plc announced that it has received $30 million in funding from Sanofi Foreign Participations B.V.

New minor risk - Share price stability

MeiraGTx Holdings plc Announces an Oral Presentation and Eight Posters At the European Society of Gene and Cell Therapy 2023 Annual Congress

Does MeiraGTx Holdings (NASDAQ:MGTX) Have A Healthy Balance Sheet?

Consensus revenue estimates decrease by 12%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MeiraGTx Holdings plc Announces Positive Clinical Data from the AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

MeiraGTx Holdings plc to Present 12-Month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MeiraGTx Holdings plc announced that it expects to receive $61.525 million in funding from Perceptive Advisors LLC, 683 Capital Management, LLC, Prosight Management, LP, Adage Capital Management, L.P.

Calculating The Intrinsic Value Of MeiraGTx Holdings plc (NASDAQ:MGTX)

MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are Reducing Their Forecasts For This Year

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased by 7.4% to US$31.00

CEO, President & Director exercised options and sold US$222k worth of stock

CEO, President & Director exercised options and sold US$170k worth of stock

MeiraGTx Holdings plc cAnnounces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Consensus revenue estimates fall by 26%

MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are More Bearish Than They Used To Be

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

MeiraGTx Holdings plc announced that it has received $24.999994 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

MeiraGTx GAAP EPS of -$0.76, revenue of $10.76M

MeiraGTx Holdings plc announced that it expects to receive $100 million in funding from Perceptive Advisors LLC

MeiraGTx Holdings plc announced that it expects to receive $100 million in funding from Perceptive Advisors LLC

MeiraGTx inks $100M debt agreement backed by manufacturing facilities

MeiraGTx Holdings plc Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients Treated with Botaretigene Sparoparvovec (AAV-RPGR) Compared to Untreated Randomized Control

Consensus forecasts updated

Price target decreased to US$30.57

MeiraGTx Holdings plc Presents Clinical Data on Botaretigene Sparoparvovec for Treatment of X-Linked Retinitis Pigmentosa at Association for Research in Vision and Ophthalmology 2022 Annual Meeting

MeiraGTx Holdings plc, Annual General Meeting, Jun 07, 2022

MeiraGTx Holdings (NASDAQ:MGTX) Is In A Good Position To Deliver On Growth Plans

MeiraGTx Appoints Debra Yu to Board of Directors

Insufficient new directors

Insufficient new directors